Abstract
A double-blind controlled clinical trial of cross-over design for the treatment of headache was conducted in 88 women identified during a community survey as having headaches with the features of migraine. Of 79 subjects who completed the trial, 40 benefited from oral ergotamine tartrate and 46 benefited from the placebo. There was no evidence that ergotamine in doses of 2 or 3 mg. was more effective than the placebo. Ergotamine aggravated the attack significantly more often than the placebo. Neither the colour of the tablets nor the order of therapy significantly affected the results of the treatment.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barrie M. A., Fox W. R., Weatherall M., Wilkinson M. I. Analysis of symptoms of patients with headaches and their response to treatment with ergot derivatives. Q J Med. 1968 Apr;37(146):319–336. [PubMed] [Google Scholar]
- CROOKS J., STEPHEN S. A., BRASS W. CLINICAL TRIAL OF INHALED ERGOTAMINE TARTRATE IN MIGRAINE. Br Med J. 1964 Jan 25;1(5377):221–224. doi: 10.1136/bmj.1.5377.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Waters W. E. Community studies of the prevalence of headache. Headache. 1970 Jan;9(4):178–186. doi: 10.1111/j.1526-4610.1970.hed0904178.x. [DOI] [PubMed] [Google Scholar]